Is GLP-1 (7-37) FDA approved?

GLP-1 (7-37) is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is GLP-1 (7-37) administered in research settings?

In research settings, GLP-1 (7-37) is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Retatrutide administered in research settings?

In research settings, Retatrutide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›GLP-1 (7-37) vs Retatrutide

Peptide Comparison

GLP-1 (7-37) vs Retatrutide

Name: GLP-1 (7-37) vs Retatrutide — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Metabolic peptides.

GLP-1 (7-37)

GLP-1 fragment

Fat LossNot EvaluatedResearch Only

33 providers listed

Full GLP-1 (7-37) profile →

Retatrutide

GLP-3

Fat LossUnder clinical reviewResearch Only

Half-life: ~6 days

96 providers listed

Full Retatrutide profile →

Bottom line

Retatrutide carries stronger published evidence (Meta-analysis, 10 key studies) than GLP-1 (7-37) (RCT, 1); both are research compounds.

Quick Verdict

GLP-1 (7-37)

Half-life

—

Retatrutide

Half-life

~6 days

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Retatrutide
Further along in FDA review	Retatrutide
More provider options (33 vs 96)	Retatrutide

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

GLP-1 (7-37)

Retatrutide

Mechanism Family

Metabolic

Half-life

—

~6 days

FDA Status

not evaluated

Under clinical review

Admin Routes

subcutaneous, intravenous

subcutaneous

Availability

Research Only

Providers

33 listed

96 listed

FDA Update

—

Under clinical review

Avail. Notes

—

Triple GIP/GLP-1/glucagon agonist by Eli Lilly. Pivotal Phase 3 readouts across obesity (TRIUMPH-1, May 2026), obesity + knee osteoarthritis (TRIUMPH-4, Dec 2025), type 2 diabetes (TRANSCEND-T2D-1, Mar 2026), obesity + type 2 diabetes (TRIUMPH-2, Jul 2026), and severe obesity + cardiovascular disease (TRIUMPH-3, Jul 2026); OSA trial in program. Not FDA-approved; Lilly plans to submit a Biologics License Application (BLA) to FDA in Q1 2027. NCT05929066.

Research Evidence

GLP-1 (7-37)

RCT · 1 key study · dated evidence base — most recent 1999

Retatrutide

Meta-analysis · 10 key studies · most recent 2026

Research Citations

GLP-1 (7-37)

RCT1999 · Diabetes Care

GLP-1 treatment of obese patients with type 2 diabetes mellitus: improvement of insulin responsiveness by red…

Retatrutide

Meta-analysis2026 · Ann Intern Med

Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Revi…

RCT2026 · J Clin Endocrinol Metab

Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.

RCT2025 · Diabetes, Obesity and Metabolism

Design of the TRIUMPH phase 3 clinical trial programme for retatrutide in obesity and cardiometabolic disease

RCT2023 · New England Journal of Medicine

Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial

+6 more

About GLP-1 (7-37)

Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways.

Research Areas

appetite suppressioninsulin sensitivityblood glucose regulation

About Retatrutide

Triple GIP/GLP-1/glucagon receptor agonist; targets three pathways for synergistic fat reduction

Research Areas

profound weight lossappetite suppressionmetabolic improvement

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

GLP-1 (7-37)

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Acute pancreatitisPregnancy (discontinue; not for use in pregnancy)Gallbladder disease / cholelithiasisDiabetic retinopathy complications (reported with GLP-1 receptor agonist use)Severe GI disease / gastroparesis / ileus riskHypoglycemia when combined with insulin or sulfonylureasAcute kidney injury secondary to volume depletion

Class-based (investigational)

Retatrutide

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Class-based (investigational)

Price (per mg)

GLP-1 (7-37)

Not enough vendor pricing yet.

Retatrutide

$9.14/mg

$8.50 – $11.45 range

12 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

GLP-1 (7-37)

33 listed

Browse directory →

Providers offering

Retatrutide

96 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Metabolic Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). GLP-1 (7-37) vs Retatrutide — Per-mg Price Comparison. Retrieved September 12, 2026, from https://peptidebase.io/peptides/compare/glp-1-7-37/retatrutide

https://peptidebase.io/peptides/compare/glp-1-7-37/retatrutide Methodology License Download JSON Download CSV